Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122912401> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2122912401 endingPage "157" @default.
- W2122912401 startingPage "153" @default.
- W2122912401 abstract "Purpose Rofecoxib and celecoxib have been recently introduced and promoted as ‘safer’ non-steroidal anti-inflammatory drugs (NSAIDs) regarding gastric toxicity. The primary aim was to measure their uptake and any impact on conventional NSAID prescribing. A secondary aim was to assess any change in proton pump inhibitor (PPI) prescribing. Methods Prescribing data in terms of defined daily doses (DDDs) were pooled from 1997 onwards. Linear trends in the data were tested for using regression analyses. Direct comparisons were made between the April–June quarter of the year 1999 (i.e. before the introduction of rofecoxib and celecoxib) and the same quarter 3 years later. Results Overall NSAID prescribing in Northern Ireland was found to be increasing linearly at an estimated rate of 154 000 DDDs per quarter since the introduction of celecoxib and rofecoxib. The rate of increase in the volume of prescribing of the two new drugs was found to be four times the rate of decrease in prescribing of the ‘older’ NSAIDs. Overall prescribing of anti-inflammatory agents had increased from 37.8 to 47.7 DDDs/1000 patients/day over 3 years with no effect on the upward trend in PPI prescribing. Conclusions The introduction of rofecoxib and celecoxib has increased prescribing volume of anti-inflammatory agents by 26% in Northern Ireland over the 3-year period. This could pose safety problems in the future as more people are being prescribed anti-inflammatory agents. Copyright © 2003 John Wiley & Sons, Ltd." @default.
- W2122912401 created "2016-06-24" @default.
- W2122912401 creator A5015880040 @default.
- W2122912401 creator A5033084584 @default.
- W2122912401 creator A5063333385 @default.
- W2122912401 creator A5071015343 @default.
- W2122912401 date "2003-05-22" @default.
- W2122912401 modified "2023-09-25" @default.
- W2122912401 title "Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland" @default.
- W2122912401 cites W2001350224 @default.
- W2122912401 cites W2024233889 @default.
- W2122912401 cites W2125003309 @default.
- W2122912401 cites W2163756514 @default.
- W2122912401 cites W2172253009 @default.
- W2122912401 cites W2313437711 @default.
- W2122912401 cites W2330496155 @default.
- W2122912401 cites W2333044470 @default.
- W2122912401 doi "https://doi.org/10.1002/pds.866" @default.
- W2122912401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15072114" @default.
- W2122912401 hasPublicationYear "2003" @default.
- W2122912401 type Work @default.
- W2122912401 sameAs 2122912401 @default.
- W2122912401 citedByCount "14" @default.
- W2122912401 countsByYear W21229124012014 @default.
- W2122912401 countsByYear W21229124012017 @default.
- W2122912401 countsByYear W21229124012021 @default.
- W2122912401 crossrefType "journal-article" @default.
- W2122912401 hasAuthorship W2122912401A5015880040 @default.
- W2122912401 hasAuthorship W2122912401A5033084584 @default.
- W2122912401 hasAuthorship W2122912401A5063333385 @default.
- W2122912401 hasAuthorship W2122912401A5071015343 @default.
- W2122912401 hasConcept C126322002 @default.
- W2122912401 hasConcept C166957645 @default.
- W2122912401 hasConcept C181199279 @default.
- W2122912401 hasConcept C185592680 @default.
- W2122912401 hasConcept C194828623 @default.
- W2122912401 hasConcept C23276603 @default.
- W2122912401 hasConcept C2426938 @default.
- W2122912401 hasConcept C2776467144 @default.
- W2122912401 hasConcept C2776865356 @default.
- W2122912401 hasConcept C2778582115 @default.
- W2122912401 hasConcept C2779689624 @default.
- W2122912401 hasConcept C2780035454 @default.
- W2122912401 hasConcept C55493867 @default.
- W2122912401 hasConcept C71924100 @default.
- W2122912401 hasConcept C85079727 @default.
- W2122912401 hasConcept C95457728 @default.
- W2122912401 hasConcept C98274493 @default.
- W2122912401 hasConceptScore W2122912401C126322002 @default.
- W2122912401 hasConceptScore W2122912401C166957645 @default.
- W2122912401 hasConceptScore W2122912401C181199279 @default.
- W2122912401 hasConceptScore W2122912401C185592680 @default.
- W2122912401 hasConceptScore W2122912401C194828623 @default.
- W2122912401 hasConceptScore W2122912401C23276603 @default.
- W2122912401 hasConceptScore W2122912401C2426938 @default.
- W2122912401 hasConceptScore W2122912401C2776467144 @default.
- W2122912401 hasConceptScore W2122912401C2776865356 @default.
- W2122912401 hasConceptScore W2122912401C2778582115 @default.
- W2122912401 hasConceptScore W2122912401C2779689624 @default.
- W2122912401 hasConceptScore W2122912401C2780035454 @default.
- W2122912401 hasConceptScore W2122912401C55493867 @default.
- W2122912401 hasConceptScore W2122912401C71924100 @default.
- W2122912401 hasConceptScore W2122912401C85079727 @default.
- W2122912401 hasConceptScore W2122912401C95457728 @default.
- W2122912401 hasConceptScore W2122912401C98274493 @default.
- W2122912401 hasIssue "3" @default.
- W2122912401 hasLocation W21229124011 @default.
- W2122912401 hasLocation W21229124012 @default.
- W2122912401 hasOpenAccess W2122912401 @default.
- W2122912401 hasPrimaryLocation W21229124011 @default.
- W2122912401 hasRelatedWork W1991307214 @default.
- W2122912401 hasRelatedWork W2008225822 @default.
- W2122912401 hasRelatedWork W2008570013 @default.
- W2122912401 hasRelatedWork W2053833211 @default.
- W2122912401 hasRelatedWork W2084602324 @default.
- W2122912401 hasRelatedWork W2094903599 @default.
- W2122912401 hasRelatedWork W2122912401 @default.
- W2122912401 hasRelatedWork W2138631692 @default.
- W2122912401 hasRelatedWork W2141783462 @default.
- W2122912401 hasRelatedWork W4291014994 @default.
- W2122912401 hasVolume "13" @default.
- W2122912401 isParatext "false" @default.
- W2122912401 isRetracted "false" @default.
- W2122912401 magId "2122912401" @default.
- W2122912401 workType "article" @default.